Resumen de Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation
Mónica León González, Andrés Aurelio León Peña, María Fernanda Vallejo Villalobos, Ana Karen Núñez Cortés, Alejandro Ruiz Argüelles, Guillermo José Ruiz Argüelles
Background: Following the release of the initial presentation of filgrastim (granulocyte colony-stimulating factor), several biosimilars have been developed worldwide. Objective: To study the efficacy of a Mexican biosimilar granulocyte colony-stimulating factor in a single transplant center. Methods: In a group of 19 consecutive patients with multiple sclerosis given autografts, we employed granulocyte colony-stimulating factors to mobilize stem cells from the bone marrow to the peripheral blood, either the original granulocyte colony-stimulating factor (n = 10) or a Mexican granulocyte colony-stimulating factor biosimilar (n = 9).
Results: The efficacy of both agents was similar in mobilization capacity, white blood cell count rise, stem cell collection, and kinetics of auto-engraftment. Conclusion: We conclude that both granulocyte colony-stimulating factor agents were similar in their efficacy to mobilize stem cells and usefulness in autografts. (REV INVES CLIN. 2016;68:181-3)
